The Latest Regenerative Medicine Articles from Streetwise Reports


Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million

Research Report
  ()
The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. read more >

First Cobalt Corp., Oversold, Poised for Rebound This Year?

Contributed Opinion
  ()
Peter Epstein of Epstein Research discusses the market for cobalt and profiles one company whose shares he believes could be at an attractive entry point. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >

After Financing Close, Biotech's Subsidiary to Operate Independently

Research Report
  ()
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. read more >
Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX's capital raise takes care of financing overhang on the stock." ❭
– Francois Brisebois, Laidlaw & Company